SGLT2 inhibitors show accumulating evidence of a suppressive effect on sympathetic nerve tone, which may be a mechanism for cardiovascular protection in type 2 diabetes.
Do SGLT2 inhibitors suppress sympathetic nerve activity in patients with type 2 diabetes?
SGLT2 inhibitors may suppress sympathetic nerve tone, offering a potential mechanism for their cardiovascular protective effects in type 2 diabetes.
SGLT2 inhibitors increase renal glucose excretion and thus decrease both fasting and postprandial plasma glucose levels. The effects of SGLT2 inhibition outweigh those on glycemic control and are also associated with the induction of hemodynamic changes that improve cardiovascular and renal function in people with type 2 diabetes. The exact mechanisms have not yet been completely clarified. This review is focused on the potential relationship between SGLT2 inhibition and sympathetic nerve activity. There is accumulating evidence for a suppressive effect of SGLT2 inhibitors on the sympathetic nerve tone, which might be a putative mechanism for cardiovascular protection in subjects with type 2 diabetes.
Dimova et al. (Tue,) conducted a review in Type 2 Diabetes. SGLT2 inhibitors was evaluated. SGLT2 inhibitors show accumulating evidence of a suppressive effect on sympathetic nerve tone, which may be a mechanism for cardiovascular protection in type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: